Last reviewed · How we verify
MenACWY Vaccine (menacwy-vaccine)
MenACWY Vaccine (menacwy-vaccine) from Pfizer Inc. is a marketed vaccine with key indications in Tdap booster doses and routine vaccinations for adolescents and adults. It has undergone 100 trials and 73 publications. The commercial significance of this vaccine lies in its widespread use for preventing tetanus, diphtheria, and pertussis. The pipeline developments for this vaccine are not specified. As a marketed vaccine, it has already demonstrated its clinical differentiation and efficacy. The revenue generated by this vaccine is not disclosed.
At a glance
| Generic name | menacwy-vaccine |
|---|---|
| Sponsor | Pfizer |
| Drug class | Conjugate vaccine |
| Target | Meningococcal antigens |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Tetanus, diphtheria, and pertussis toxoids adsorbed (Tdap) booster dose in individuals 11 through 64 years of age
- Routine vaccination of adolescents 11 through 12 years of age
- Routine vaccination of adolescents 13 through 18 years of age who have not previously completed the series
- Catch-up vaccination for individuals 13 through 18 years of age who have not previously completed the series
- Routine vaccination of adults 19 through 26 years of age who have not previously completed the series
- Catch-up vaccination for adults 19 through 26 years of age who have not previously completed the series
- Routine vaccination of adults 27 years of age and older who have not previously completed the series
- Catch-up vaccination for adults 27 years of age and older who have not previously completed the series
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
- Routine vaccination of individuals 11 through 64 years of age with certain risk factors
Common side effects
Drug interactions
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
- Live, attenuated vaccines
Key clinical trials
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (PHASE2)
- Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women (NA)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
- Increasing Vaccine Uptake Among Adolescents in the Rural South (NA)
- Investigating a Vaccine Against COVID-19 (PHASE2, PHASE3)
- A Study of a Candidate COVID-19 Vaccine (COV001) (PHASE1, PHASE2)
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACWY Vaccine CI brief — competitive landscape report
- MenACWY Vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI